Company Overview and News
CALGARY, Alberta, Sept. 04, 2018 (GLOBE NEWSWIRE) -- The Board of Trustees of Northview Apartment Real Estate Investment Trust (TSX:NVU.UN) ("Northview") today announced the appointment of Valery Zamuner as a Trustee of Northview.
Good afternoon, ladies and gentlemen. Welcome to WSP's Second Quarter of 2018 Results Conference Call. I would now like to turn the meeting over to Isabelle Adjahi, Senior Vice President, Investor Relations and Communications.
MONTREAL, Aug. 08, 2018 (GLOBE NEWSWIRE) -- WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”) today announced its financial and operating results for the second quarter of fiscal 2018, which ended on June 30, 2018.
MONTREAL, July 20, 2018 (GLOBE NEWSWIRE) -- WSP Global Inc. (TSX:WSP) ("WSP" or the "Corporation") will announce its 2018 second quarter results on August 8, 2018. A conference call will be held on the same day at 4:00 p.m. (Eastern Time) to discuss the results.
MONTREAL, June 18, 2018 (GLOBE NEWSWIRE) -- WSP Global Inc. (TSX:WSP) (“WSP” or the “Corporation”), today announced that Hugo Blasutta, President and Chief Executive Officer of WSP in Canada, will leave the Corporation at the end of the year. The search process to identify a successor will begin soon and the transition plan will be developed and implemented with Mr. Blasutta.
Good afternoon, ladies and gentlemen. Welcome to the WSP's First Quarter of 2018 Results Conference Call. I would now like to turn the meeting over to Isabelle Adjahi, Senior Vice President Investor Relations and Communications. Please go ahead. Ms. Adjahi.
WSP LB WSPOF
MONTREAL, May 10, 2018 (GLOBE NEWSWIRE) -- WSP Global Inc. (TSX:WSP) (“WSP” or the “Corporation”) today announced its financial and operating results for the first quarter of fiscal 2018, which ended on March 31, 2018.
2018-04-26 marketwired - 1
MONTREAL, QUEBEC--(Marketwired - April 26, 2018) - WSP Global Inc. (TSX:WSP) ("WSP" or the "Corporation") will host its annual meeting of shareholders and release its 2018 first quarter results on Thursday, May 10, 2018.
MONTREAL, QUEBEC--(Marketwired - March 22, 2018) - WSP Global Inc. (TSX:WSP) ("WSP" or the "Corporation") is pleased to announce that it has acquired UnionConsult Gruppen AS and its affiliated entities (together "UnionConsult"), a leading 160 employee Norwegian design and technical advisory firm, specialized in the Buildings sector. Based in Oslo, with 8 additional offices across Norway, UnionConsult's main expertise is in Mechanical, Electrical and Plumbing, and offers additional services in buildings engineering and architecture.
[Call Started Abruptly] Good organic growth in net revenues of 4.6%. This region delivered adjusted EBITDA and adjusted EBITDA margin before global corporate costs of $220.2 million and 13.3%, respectively. Once again, the highest among all of our reportable operating segments. The pipeline of opportunities for the Americas remain healthy and we are pleased to have been selected to provide services related to the development of the Giant Magellan Telescope, the first of the next generation of giant ground-based telescopes.
WSP LB WSPOF
MONTREAL, QUEBEC--(Marketwired - March 15, 2018) - WSP Global Inc. (TSX:WSP) ("WSP" or the "Corporation") today announced strong financial and operating results for the fiscal year and fourth quarter ended December 31, 2017.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET